title: Effect of COX-2 inhibitor after TNBS-induced colitis in Wistar rats.
abstract: Inflammatory bowel disease (IBD) is a common chronic gastrointestinal disorder characterized by alternating periods of remission and active intestinal inflammation. Some studies suggest that antiinflammatory drugs are a promising alternative for treatment of the disease. Thus, this study aimed to evaluate the effect of lumiracoxib, a selective-cyclooxygenase-2 (COX-2) inhibitor, on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis. Wistar rats (n = 25) were randomized into four groups, as follows: Group (1) Sham group: sham induced-colitis rats; Group (2) TNBS group: nontreated induced-colitis rats; Group (3) Lumiracoxib control group; and Group (4) Lumiracoxib-treated induced-colitis rats. Our results showed that rats from groups 2 and 4 presented similar histopathological damage and macroscopic injury in the distal colon as depicted by significant statistically differences (P < 0.01; P < 0.05) compared to the other two groups. Weak expression of COX-2 mRNA was detected in normal colon cells, while higher levels of COX-2 mRNA were detected in group 2 and group 4. Therapy with lumiracoxib reduced COX-2 expression by 20-30%, but it was still higher and statistically significant compared to data obtained from the lumiracoxib control group. Treatment with the selective COX-2 inhibitor lumiracoxib did not reduce inflammation-associated colonic injury in TNBS-induced experimental colitis. Thus, the use of COX-2 inhibitors for treating IBD should be considered with caution and warrants further experimental investigation to elucidate their applicability.
authors: Department of Pathology, Paulista Medical School, Federal University of Sao Paulo, Rua Botucatu, Sao Paulo, 04023-062, Brazil. a.paiotti@unifesp.br
authors: Ana Paula Ribeiro
authors: AP
authors: Paiotti
authors: Sender Jankiel
authors: SJ
authors: Miszputen
authors: Celina Tizuko Fujiyama
authors: CT
authors: Oshima
authors: Henrique
authors: H
authors: de Oliveira Costa
authors: Daniel Araki
authors: DA
authors: Ribeiro
authors: Marcello
authors: M
authors: Franco
mesh_terms: D000818:Animals; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D004008:Diclofenac / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D012333:RNA, Messenger / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D014302:Trinitrobenzenesulfonic Acid / Q000494:pharmacology
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D012333:RNA, Messenger; D004008:Diclofenac; D014302:Trinitrobenzenesulfonic Acid; C473384:lumiracoxib